Pooley N, Yazdany J, Langham J, Nicholson L, Langham S, Embleton N, Wang X, Desta B, Barut V, Hammond ER. The risk of venous thromboembolic events in adult patients with systemic lupus erythematosus: a systematic review and meta-analysis. Ann Rheum Dis 2019;78(Suppl 2):A804

Pooley N, Marjenberg Z, Embleton N, Langham S. The increasing use and acceptance of alternative statistical approaches to indirect comparison in the National Institute of Health and Care Excellence (NICE) health technology assessment (HTA) submission process. Value Health 2019:22(Suppl 3):S814

Odnoletkova I, Marjenberg Z, Pooley N, Langham S. Therapeutic benefit of orphan drugs in oncology: evidence at the point of European Marketing Authorisation. Value Health 2019;22(Suppl 3): S491

Nicholson L, Langham S, Adkins E. The patient perspective in health technology assessment reimbursement decisions for orphan drugs across different countries. Value Health 2019:22(Suppl 3):S860

Langham S, Lewis J, Pooley N, Embleton N, Langham J. A systematic review of single-inhaler triple therapy in patients with chronic obstructive pulmonary disease (COPD). Value Health 2019;22(Suppl 3):S873

Sampson CJ, Arnold R, Bryan S, Clarke P, Ekins S, Hatswell A, Hawkins N, Langham S, Marshall D, Sadatsafavi M, Sullivan W, Wilson ECF, Wrightson T. Transparency in decision modelling: what, why, who and how? Pharmacoeconomics 2019;37(11):1355–69

Langham S, Lewis J, Pooley N, Embleton N, Langham J, Han MK, Chalmers JD. Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic and descriptive review. Respir Res 2019;20(1):242

Kenworthy J, Langham S, Wright A, Dunlop W. Budget impact analysis of methoxyflurane (Penthrox®) for emergency relief of moderate-to-severe trauma pain in the Swedish setting. Value Health 2018;21(Suppl 3):S443

Wright A, Embleton N, Langham S. Choosing the right software for HTA economic models: a comparison of four programmes recommended by the National Institute for Health and Care Excellence. Value Health 2018;21(Suppl 3):S380

Langham S, Wright A, Kenworthy J, Grieve R, Dunlop WCN. Cost-effectiveness of take-home naloxone for the prevention of overdose fatalities among heroin users in the UK. Value Health 2018;21(4):407–15. Open access ‘R’ and ‘Excel model’

Langham S, Lewis J. Health technology assessment of companion diagnostics alongside therapeutic agents in oncology: experience of the NICE technology appraisal programme. Value Health 2018;21(Suppl 3):S272

Langham J, Langham S. Conducting and reporting indirect treatment comparisons: a critical appraisal of oncology technology appraisals. Value Health 2018;21(Suppl 3):S68

Kriz A, Migliore A, Wright A, Piaggio T. Modelled effects of a pediatric triple-chamber-bag (3CB) system on payer costs and clinical outcomes in pre-term neonates across France, Germany, and Italy. Value Health 2018;21(Suppl 3): S216–7

Langham S, Wright A, Kenworthy J, Grieve R, Dunlop WCN. Cost-effectiveness of take-home naloxone for the prevention of overdose fatalities among heroin users in the UK. Value Health 2018;21(4):407–15.

Langham S, Wright A, Shaw H, Bryson S, O’Leary S. Budget impact analysis of oral glycopyrronium bromide (Sialanar™) for the symptomatic treatment of severe sialorrhoea (drooling) in the UK setting. Value Health 2017;20(9):A720

Langham J, Langham S. European real-world data sources to characterise flares in patients with systemic lupus erythematosus: a review. Value Health 2017;20(9):A571

Langham S, Kenworthy JJ, Grieve R, Dunlop W. Cost-effectiveness of take-home naloxone for the prevention of fatalities from heroin overdose in the UK. Value Health 2016:19(7):A525–6